These conditions prompted DCs and T lymphocytes, especially immature DCs and CD8(+) CTLs, to further trigger T lymphocyte-mediated anti-tumor immunity, enhancing the efficacy of angiogenesis targeting. The gene discussed is CD8A; the disease is neoplasm.